

## Theraclion Reports 2014 Revenues of 800 K€

- Echopulse® commercialization commenced; consumables sales increased by 73%
  - New commercial agreement signed with Institut de Radiologie de Paris  
(Paris Radiology Institute)

**Paris - FRANCE, January 29<sup>th</sup> 2015 – THERACLION** (Alternext, ISIN: FR0010120402 – Ticker: ALTHE), a company specialized in cutting-edge medical equipment for Echotherapy, today reported its annual sales revenues for 2014. The Company also announced first commercial agreement of 2015 with the Institut de Radiologie de Paris (Paris Radiology Institute), the largest center of radiology in France.

### 2014 Sales revenues

In 2014, total revenues realized by Theraclion were 800 K€ versus 15 K€ in 2013.

	FY13 (12 months)	FY14 (12 months)
<b>Total Sales Revenues</b>	<b>15 K€</b>	<b>800 K€</b>
<i>Sales of equipment</i>	0 K€	774 K€
<i>Sales of consumables</i>	15 K€	26 K€

97% of 2014 revenues were comprised of sales to three major customers: the American Hospital of Paris (France), the German clinic Helios Klinik Schkeuditz and the Turkish distributor Penta. This was the first year that equipment was commercialized; the Echopulse® sold in 2013 was a demo device and recorded as extraordinary income.

Revenues from consumables increased by 73% and validate Theraclion's business model based on equipment and recurring revenues.

During the second half of 2014, Theraclion signed the first commercial agreement with a private imaging center, SELAS du Nedon in Istres (France). The impact of this agreement on revenues will start in 2015.

## Installation of the Echopulse® at the Paris Radiology Institute (IRP): a solution for fibroadenoma treatment

The Paris Radiology Institute is the largest radiology center in France and one of the most important imaging center for breast in Europe. More than 150 mammographies are performed each day. The choice of Echopulse® by this KOL is a strong sign of potential adoption.

The introduction of the Echopulse® solution completes the range of imaging modalities proposed by this Institute with a treatment for breast fibroadenoma, an indication in which this center is leader with an international reputation.

*« We are proud to propose now an innovation and non-invasive solution to our patients with a fibroadenoma. The Echopulse® is an elegant and rapid solution that avoids general anesthesia and, obviously, the resulting scar from surgery. For patients that will go for this method, the echotherapy will allow a quick and ambulatory procedure. People shall return to a normal activity immediately after the treatment. »* said Dr. Alain Dana, the managing partner of the Paris Radiology Institute

*« Theraclion achieved important milestones during the second half of 2014. The strengthening of the management team and the appointment of three country managers (VPs of Northern Europe, Central Europe & Asia) led to encouraging results including the first sale in a major private clinic in Germany. We are also pleased to announce today the installation of Echopulse® in the Paris Radiology Institute, the most important imaging center in France. These new commercial sites and the prominent publications in peer-reviewed papers, with positive results, support our conviction that our treatment solution is set to become a credible alternative to surgery. We continue to pursue our efforts in the optimization of our technology and its commercialization in France and abroad. »* said David Caumartin, CEO of Theraclion.

### About Theraclion:

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on cutting-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 23 people, 65 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: [www.theraclion.com](http://www.theraclion.com).

### Theraclion is listed on Alternext Paris

Eligible for the PEA-PME, a tax-exempt share savings plan for SMEs

Ticker symbol: ALTHE – ISIN code: FR0010120402

Mnémonique: ALTHE – Code ISIN : FR0010120402



Next financial press release: annual results 2014, March 19<sup>th</sup> 2015

**Contact :**

**Sarah Ankri**

Theraclion

CFO

Phone: +33 (0)1 55 48 90 70

[investors@theraclion.com](mailto:investors@theraclion.com)

**NewCap**

Financial Communications & Investor Relations

Emmanuel Huynh / Sophie Boulila

Phone: +33 (0)1 44 71 94 91

[theraclion@newcap.fr](mailto:theraclion@newcap.fr)

**ALIZE RP**

Press Relations

Caroline Carmagnol / Valentine Boivin

Phone : + 33 (0)1 44 54 36 63

[theraclion@alizerp.com](mailto:theraclion@alizerp.com)